Filing Details
- Accession Number:
- 0001341004-19-000565
- Form Type:
- 13D Filing
- Publication Date:
- 2019-11-26 11:36:39
- Filed By:
- Ripple Labs Inc.
- Company:
- Moneygram International Inc (NASDAQ:MGI)
- Filing Date:
- 2019-11-26
- SEC Url:
- 13D Filing
Ownership Summary
Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.
Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
---|---|---|---|---|---|---|
Ripple Labs Inc | 6,237,523 | 0 | 6,237,523 | 0 | 6,237,523 | 9.95% |
Filing
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
(Rule 13d-101)
UNDER THE SECURITIES EXCHANGE ACT OF 1934
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO
§ 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO
§ 240.13d-2(a)
(Amendment No. 1)
MONEYGRAM INTERNATIONAL, INC.
(Name of Issuer)
Common Stock, par value $0.01 per share
(Title of Class of Securities)
60935Y208
(CUSIP Number)
Amr Razzak
Skadden, Arps, Slate, Meagher & Flom LLP
525 University Avenue
Palo Alto, California 94301
(650) 470-4533
and
Brooks Stough
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP
One Bush Plaza. Suite 1200
San Francisco, CA 94104
(415) 801-4850
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
November 22, 2019
(Date of Event Which Requires Filing of This Statement)
If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of §§
240.13d-1(e), 240.13d-1(f) or 13d-1(g), check the following box. ☐
Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.
1 The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent
amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise
subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
CUSIP No. 60935Y208 | 13D |
1 | NAME OF REPORTING PERSONS | ||||
Ripple Labs Inc. | |||||
2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) | ☐ | ||
(b) | ☒ | ||||
3 | SEC USE ONLY | ||||
4 | SOURCE OF FUNDS | ||||
WC | |||||
5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E) | ☐ | |||
6 | CITIZENSHIP OR PLACE OF ORGANIZATION | ||||
Delaware | |||||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 7 | SOLE VOTING POWER | | ||
6,237,523 | | ||||
| |||||
8 | SHARED VOTING POWER | | |||
-0- | | ||||
| |||||
9 | SOLE DISPOSITIVE POWER | | |||
6,237,523 | | ||||
| |||||
10 | SHARED DISPOSITIVE POWER | | |||
-0- | | ||||
| |||||
11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON | ||||
6,237,523 | |||||
12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES | ☐ | |||
13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) | ||||
9.95%† | |||||
14 | TYPE OF REPORTING PERSON | ||||
CO | |||||
† Based on 62,689,081 shares of common stock outstanding as
of November 22, 2019, as disclosed by the Issuer to the Reporting Person.
Introductory Note
This Amendment No. 1 (“Amendment No. 1”) amends and supplements the statement on Schedule 13D originally filed by the Reporting Person on June 27, 2019 (the “Schedule 13D”) and
relating to the common stock, par value $0.01 per share (the “Common Stock”) of MoneyGram International, Inc., a Delaware corporation (the “Issuer”), and is being filed pursuant to Section 13(d) of the Securities Exchange Act of 1934 (the “Exchange
Act”). Each item below amends and supplements the information disclosed under the corresponding Item of the Schedule 13D. Except as specifically provided herein, this Amendment No. 1 does not modify any of the information previously reported in the
Schedule 13D. When disclosure made in one Item in the Schedule 13D prior to this Amendment No. 1 was incorporated by reference into another Item, amendments made herein to any such first Item are incorporated into each such second Item of the
Schedule 13D.
Item 2. | Name of Person Filing |
Item 2 is hereby amended and supplemented as follows:
Schedule A to the Schedule 13D is amended and restated in its entirety as set forth as Schedule A hereto.
Item 3. | Source and Amount of Funds or Other Consideration. |
Item 3 is hereby amended and supplemented as follows:
On November 22, 2019, an Additional Closing (as defined in the SPA) occurred under the SPA. In connection with such Additional Closing, MoneyGram International, Inc. (the “Issuer”)
issued to the Reporting Person (i) 626,600 shares of Common Stock (the “Additional Shares”) and (ii) a Warrant to purchase 4,251,449 shares of Common Stock (the “Additional Warrant” and together with the Additional Shares, the “Additional
Investment”).
The Reporting Person funded the Additional Investment through the Letter of Credit, as described in further detail in Item 4.
Item 4. | Purpose of Transaction. |
Item 4 is hereby amended and supplemented as follows:
On November 14, 2019, pursuant to the SPA and the Letter of Credit, the Issuer exercised a Letter of Credit Draw by delivering a Draw Notice to the Reporting Person and the LOC Bank
for an amount equal to $20 million in the aggregate. On November 22, 2019, pursuant to the SPA, the Reporting Person purchased and the Issuer issued the (i) Additional Shares at a purchase price of $4.10 per share and (ii) the Additional Warrant
with a per share reference price of $4.10 per share of Common Stock, for an aggregate purchase price of $20 million.
As a result of the Additional Investment, the Issuer no longer has the right under the SPA or the Letter of Credit to issue or sell to the Reporting Person, or to cause the
Reporting Person to purchase or acquire, additional shares of Common Stock or Warrants.
Item 5. | Interest in Securities of the Company. |
Item 5 is hereby amended and supplemented as follows:
(a), (b) The Reporting Person beneficially owns, and has sole voting and investment power over, the 6,237,523 shares of Common Stock that the Issuer issued to the Reporting Person pursuant to the SPA in connection with the Initial Investment and the Additional Investment, which represents 9.95% of the issued and outstanding shares
of Common Stock as of November 22, 2019, after giving effect to the issuance of the shares of Common Stock pursuant to the SPA in connection with the Additional Investment. Additionally, the Reporting Person holds the Initial Warrant and the
Additional Warrant, which the Reporting Person may exercise, in whole or in part, for up to an additional 5,957,600 shares of Common Stock if (A) such exercise would not result in the Reporting Person beneficially owning 9.95% or more of the Issuer’s
voting securities or (B) certain regulatory approvals required for the Reporting Person to acquire such Common Stock have been obtained as of such time.
As a result of the Additional Investment, the Issuer no longer has the right under the SPA or the Letter of Credit to issue or sell to the Reporting Person, or to cause the
Reporting Person to purchase or acquire, additional shares of Common Stock or Warrants.
(c) Except as set forth in Items 3 and 4 above, neither the Reporting Person, nor, to the best knowledge of the Reporting Person, any of the persons named in Schedule A hereto, has
effected any transactions in the equity securities of the Issuer during the past 60 days.
(d) Neither the Reporting Person and, to the best knowledge of the Reporting Person, no other person, has the right to receive or the power to direct the receipt of dividends from,
or the proceeds from the sale of, the securities of the Issuer reported herein.
SIGNATURE
After reasonable inquiry and to the best of its knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.
Dated: November 26, 2019
RIPPLE LABS INC. | ||||
By: | /s/ Sameer Dhond | |||
Name: | Sameer Dhond | |||
Title: | Deputy General Counsel |
Schedule A
Name | Business Address | Principal Occupation | Officer/Director | Citizenship |
Bradley Garlinghouse | 315 Montgomery Street, Floor 2, San Francisco, CA 94104 | CEO, Ripple Labs Inc. | Officer and Director | United States |
Ron Will | 315 Montgomery Street, Floor 2, San Francisco, CA 94104 | CFO, Ripple Labs Inc. | Officer | United States |
Stuart Alderoty | 315 Montgomery Street, Floor 2, San Francisco, CA 94104 | General Counsel, Ripple Labs Inc. | Officer | United States |
Christian Larsen | c/o Ripple Labs Inc. 315 Montgomery Street, Floor 2, San Francisco, CA 94104 | Executive Chairman of the Board of Directors of Ripple Labs Inc. | Director | United States |
Susan Athey | 655 Knight Way, Stanford, CA 94305 Mail Code: 4800 | Professor of Economics, Stanford Graduate School of Business | Director | United States |
Kenneth Kurson | c/o Sea of Reeds 1030 15th Street NW Suite 266 Washington DC 20005 | Editor in Chief, Observer Media | Director | United States |
Benjamin Lawsky | 35 East 62nd St. New York, NY 10065 | CEO, The Lawsky Group | Director | United States |
Anja Manuel | RiceHadleyGates LLC c/o OMM 2765 Sand Hill Road Menlo Park, CA 94025 | Partner, RiceHadleyGates, LLC | Director | United States |
Yoshitaka Kitao | 19F, Izumi Garden Tower 1-6-1, Roppongi, Minato-ku, Tokyo, 106-6019, Japan | President and CEO, SBI Holdings Inc. | Director | Japan |
Gene Sperling | c/o Ripple Labs Inc. 315 Montgomery Street, Floor 2, San Francisco, CA 94104 | President, Sperling Economic Strategies | Director | United States |
Craig Phillips | c/o Ripple Labs Inc. 315 Montgomery Street, Floor 2, San Francisco, CA 94104 | Consultant | Director | United States |
Page 5 of 5